根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 规定，公司应当在回购期间每个月的前三个交易日内披露截至上月末的回购进展 情况。现将公司截至上月末的回购股份进展情况公告如下： 证券代码：301367 证券简称：怡和嘉业 公告编号：2024-032 北京怡和嘉业医疗科技股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 11 日召开公司第三届董事会第七次会议和第三届监事会第七次会议，审议通过 《关于回购公司股份方案的议案》，同意公司以不低于人民币 3,000 万元（含本 数）且不超过人民币 6,000 万元（含本数）的超募资金以集中竞价交易方式回购 公司已发行的人民币普通股（A 股）股票，用于实施员工持股计划或股权激励， 回购价格不超过人民币 144.02 元/股（含本数）。回购股份的实施期限为自公司 董事会审议通过回购方案之日起不超过 12 个月。 具体内容详见公司于 2024 年 4 月 12 日、2024 年 4 月 1 ...

Investment Rating - The investment rating for the company is "Buy" [13] Core Views - The company has shown resilience in the home respiratory device market, particularly in the U.S., where it holds the second-largest market share. The company is expected to see gradual improvement in operating performance starting in 2024, with a focus on expanding its consumables business [4][13] - Revenue projections for 2024-2026 are estimated at 1.131 billion, 1.330 billion, and 1.570 billion yuan, with corresponding growth rates of 0.7%, 17.6%, and 18.1% respectively. Net profit attributable to the parent company is expected to reach 329 million, 403 million, and 485 million yuan, with growth rates of 10.6%, 22.5%, and 20.4% [4][13] Financial Performance and Forecast - In 2023, the company reported a revenue of 1.122 billion yuan, a year-over-year decrease of 20.7%, and a net profit of 297 million yuan, down 21.8% year-over-year. The first quarter of 2024 saw a revenue of 192 million yuan, a decrease of 60.02% year-over-year, and a net profit of 50 million yuan, down 67.89% year-over-year [13][14] - The company’s gross margin for 2023 was 39.87%, with a slight increase of 2.77% year-over-year. The consumables segment generated 195 million yuan in revenue, with a gross margin of 64.91%, reflecting a year-over-year increase of 2.10% [13][14] Market Position and Strategy - The company has established a data-driven subsidiary in France to enhance its service offerings in Europe, addressing local healthcare reimbursement issues and facilitating partnerships with local distributors [7] - The company is increasing its investment in the consumables business, particularly in the U.S. and European markets, with plans to build a consumables team and distribute masks to sleep monitoring institutions to enhance brand recognition [13][14]

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-031 北京怡和嘉业医疗科技股份有限公司 关于2023年年度股东大会增加临时提案暨股东大会补充 通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 12 日在 中国证监会指定的信息披露网站巨潮资讯网（http://www.cninfo.com.cn/）披露了《关于 召开公司 2023 年年度股东大会的通知》（公告编号：2024-023），定于 2024 年 5 月 9 日以现场表决与网络投票相结合的方式召开 2023 年年度股东大会。 2024 年 4 月 26 日，公司董事会接到股东珠海合晅投资中心（有限合伙）（以下简 称"合晅投资"）及其一致行动人上海盛旻创业投资合伙企业（有限合伙）（以下简称 "盛旻创投"）、南京合灏创业投资合伙企业（有限合伙）（名称曾为"深圳市合灏创 业投资企业（有限合伙）"，以下简称"合灏创投"）提交的《关于提请增加股东大会 临时提案的函》，提请公司董事会将《关于补选公司第三届董事会非独 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-030 北京怡和嘉业医疗科技股份有限公司 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日发 布了《2024 年第一季度报告》，并披露于中国证监会指定的创业板信息披露网站巨潮资 讯网（http://www.cninfo.com.cn）。 为便于广大投资者更深入全面地了解公司情况，公司定于 2024 年 4 月 26 日（星期 五）15:00-16:00 在深圳证券交易所"互动易"平台"云访谈"栏目举行 2024 年第一季 度业绩说明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆深圳证券交 易所"互动易"平台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业绩说 明会。 出席本次业绩说明会的人员拟定为：副总经理兼董事会秘书杜祎程先生、副总经理 兼财务总监暴楠先生。具体以当天实际参加会议人员为准。 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向广大投资 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-028 北京怡和嘉业医疗科技股份有限公司 第三届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）第三届监事会第八 次会议于 2024 年 4 月 23 日在公司会议室以现场结合通讯方式召开，会议通知已 于 2024 年 4 月 18 日以书面、电子邮件方式发出并送达全体监事。会议由公司监 事会主席肖爱军先生召集并主持。本次会议应出席的监事 3 人，实际出席的监事 3 人，其中监事孟晓英士以通讯方式参加会议。公司董事会秘书列席本次会议。 本次监事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和《北 京怡和嘉业医疗科技股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 经全体与会监事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于公司 2024 年第一季度报告全文的议案》； 经审议，监事会认为公司《2024 年第一季度报告》的编制和审核程序符合法 律、 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-027 北京怡和嘉业医疗科技股份有限公司 第三届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 三、备查文件 二、董事会会议审议情况 经全体与会董事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于公司 2024 年第一季度报告全文的议案》； 经审议，董事会认为公司《2024 年第一季度报告》的编制和审核程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2024 年第一季度的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案经公司董事会审计委员会审议通过。 一、董事会会议召开情况 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2024 年第一季度报告》。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）第三届董事会第 八次会议于 2024 年 4 月 23 日在公司会议室以现场结合通讯的方式召开，会议通 知已于 2024 年 4 月 18 日以书面、电子邮件方式发出并送达全体董 ...

Financial Performance - The company's revenue for Q1 2024 was ¥192,086,116.73, a decrease of 60.02% compared to ¥480,444,800.79 in the same period last year[5] - Net profit attributable to shareholders was ¥49,913,780.97, down 67.89% from ¥155,448,543.29 year-on-year[5] - The basic earnings per share decreased to ¥0.78, a decline of 67.90% from ¥2.43 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 192,086,116.73, a decrease of 60% compared to CNY 480,444,800.79 in the same period last year[18] - Net profit for Q1 2024 was CNY 5,079,630.98, a significant decline from CNY 50,553,898.72 in Q1 2023[19] - Total comprehensive income for Q1 2024 was CNY 50,540,848.17, compared to CNY 156,867,930.24 in Q1 2023, reflecting a significant decrease[20] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.78, down from CNY 2.43 in Q1 2023[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,982,238,303.41, an increase of 2.18% from ¥2,918,544,550.84 at the end of the previous year[5] - The company's accounts receivable increased to CNY 122,887,031.61 from CNY 108,576,764.77, reflecting a growth of approximately 13%[16] - The total liabilities increased to CNY 144,768,017.31 from CNY 131,615,112.91, representing a rise of approximately 10%[17] - The company’s equity attributable to shareholders increased to CNY 2,829,191,066.12 from CNY 2,779,290,335.70, showing an increase of about 1.8%[17] Cash Flow - The net cash flow from operating activities was ¥75,677,651.08, a slight decrease of 0.74% compared to ¥76,241,811.79 in the same period last year[5] - Cash inflow from operating activities was CNY 225,013,900.38, a decrease of 48.3% from CNY 435,919,191.93 in the previous year[22] - Cash outflow for purchasing goods and services was CNY 67,359,518.06, down from CNY 220,264,794.53, indicating a reduction of 69.5%[23] - Net cash flow from investing activities was -CNY 347,230,480.53, worsening from -CNY 110,313,740.46 in the same period last year[23] - Cash and cash equivalents at the end of Q1 2024 stood at CNY 396,234,366.59, compared to CNY 317,147,107.19 at the end of Q1 2023, showing an increase of 24.9%[23] Operating Costs and Expenses - The company reported a decrease in operating costs to ¥92,687,978.22, down 63.59% from ¥254,540,430.45 in the same period last year[10] - Total operating costs for Q1 2024 were CNY 149,003,247.49, down from CNY 309,047,822.86 year-over-year[18] - Research and development expenses rose to CNY 25,133,871.27, compared to CNY 19,539,134.96 in the previous year, indicating a 28.5% increase[19] Government Support and Investments - The company received government subsidies amounting to ¥6,710,790.93, an increase of 76.31% compared to ¥3,806,148.00 in the previous year[10] - The company’s investment income decreased to ¥6,276,520.58, a decline of 39.75% from ¥10,416,871.94 year-on-year, primarily due to changes in financial product returns[10] Shareholder Information - The total number of unrestricted shares held by the top 10 shareholders remains unchanged at 23,625,153 shares, with all being subject to lock-up until November 1, 2025[15] - The company has a total of 8,383,291 shares held by shareholder Zhuang Zhi, representing 13.10% of the total shares[14] - The company has a total of 5,917,948 shares held by shareholder Chen Bei, representing 9.25% of the total shares[14] - The company has a total of 4,888,804 shares held by Beijing Runmai Investment Development Center, representing 7.64% of the total shares[14] - The company has a total of 4,083,316 shares held by shareholder Xu Jian, representing 6.38% of the total shares[14] - The company has a total of 3,838,225 shares held by Shenzhen Maixing Investment Management Center, representing 6.00% of the total shares[14] - The company has a total of 3,815,625 shares held by Nengjin Co., Ltd., representing 5.96% of the total shares[14] - The company has a total of 2,088,822 shares held by Zhang Hongcheng, representing 3.26% of the total shares[14] Other Information - The company reported a significant decrease in cash and cash equivalents, with a balance of ¥397,338,328.09 as of March 31, 2024, down from ¥670,354,040.76 at the beginning of the period, representing a decline of approximately 40.6%[15] - The trading financial assets increased to ¥2,183,328,000.00 from ¥1,812,460,000.00, marking a growth of about 20.4%[15] - The company did not report any net profit from subsidiaries prior to consolidation in Q1 2024, consistent with Q1 2023[20] - The company has not yet adopted the new accounting standards as of the first quarter of 2024[24] - The first quarter report was not audited[24] - The company experienced a foreign exchange impact of CNY 896,845.76 on cash and cash equivalents[23]

Investment Rating - The report initiates coverage with a recommendation to actively monitor the company, identified as a leading domestic manufacturer of home ventilators, with an expected compound annual growth rate (CAGR) of 17.4% in net profit over the next three years [9]. Core Insights - The global market for home ventilators is projected to reach approximately $11.17 billion by 2030, with a CAGR of 9% from 2023 to 2030. The domestic market is expected to grow significantly, reaching around 4.8 billion yuan by 2030, with a CAGR of 18% during the same period [2][7]. - The company has successfully increased its market share in the global home ventilator market from 4.5% in 2020 to 17.7% in 2022, positioning itself as the second-largest player following Philips [8][7]. - The company has a comprehensive product line in the respiratory health sector, with product quality comparable to leading international brands, and has made significant advancements in product innovation and iteration [3][7]. Summary by Sections Company Overview - The company is recognized as a leading domestic manufacturer of home ventilators, with a strong focus on expanding its overseas market presence [29][35]. - The company has demonstrated strong profitability, with a notable increase in the proportion of overseas business [41][50]. - The management team possesses extensive experience in the medical device industry, contributing to the company's growth and innovation [53][60]. Industry Analysis - The respiratory health care industry is characterized by a significant unmet demand, particularly in chronic diseases such as COPD and OSA, which are prevalent in China [2][66]. - The global market for chronic disease management is substantial, with significant opportunities for domestic manufacturers to capture market share [2][66]. - The recall of Philips ventilators has reshaped the market landscape, providing an opportunity for the company to expand its presence in the U.S. market [8][50]. Company Analysis - The company has established a full product line in the respiratory health sector, continuously innovating and upgrading its products [3][41]. - The collaboration with RH (3B) has facilitated the company's entry into overseas markets, enhancing its competitive position [50][8]. - The company’s product quality is increasingly comparable to that of international leaders, with ongoing improvements in both hardware and software aspects [3][41]. Financial Forecast - The company is expected to achieve a net profit of approximately 297.34 million yuan in 2025, with a projected growth rate of 18.52% [10][9]. - The revenue for 2025 is forecasted to reach 1.31 billion yuan, reflecting a growth rate of 16.83% compared to the previous year [10][9].

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-026 北京怡和嘉业医疗科技股份有限公司 回购报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"或"怡和嘉业"） 拟使用部分首发超募资金以集中竞价方式回购公司已发行的部分人民币普通股 （A 股）股份，回购方案主要内容概括如下： 1、回购股份的种类：公司已发行的人民币普通股（A 股）股票。 2、回购股份的用途：用于实施员工持股计划或股权激励计划，若公司未能 在股份回购完成后的 36 个月内使用完毕已回购股份，尚未使用的已回购股份将 予以注销。 3、回购股份的价格：本次拟回购股份的价格不超过人民币 144.02 元/股（含 本数），未超过董事会审议通过本次回购股份方案决议前 30 个交易日公司股票 交易均价的 150%。 4、回购股份的资金总额：不低于人民币 3,000 万元且不超过人民币 6,000 万 元（均含本数），具体回购资金总额以实际使用的资金总额为准。 5、回购资金来源：本次回购股份的资金来源为公司首次公开发行股票的超 ...

关于回购股份事项前十大股东和前十大无限售条件 股东持股情况的公告 证券代码：301367 证券简称：怡和嘉业 公告编号：2024-025 北京怡和嘉业医疗科技股份有限公司 | 序号 | 股东名称 | 持股数量 （股） | 占无限售条件流通 股的比例（%） | | --- | --- | --- | --- | | 1 | 珠海合晅投资中心（有限合伙） | 7,968,347.00 | 19.74 | | 2 | 深圳市麦星投资管理中心（有限合伙）-上 | 3,838,225.00 | 9.51 | | | 海盛旻创业投资合伙企业（有限合伙） | | | | 3 | 能金有限公司 | 3,714,825.00 | 9.20 | | 4 | 张洪成 | 2,088,822.00 | 5.17 | | 5 | 蔡国方 | 1,274,936.00 | 3.16 | | 6 | 广州市金垣创业投资合伙企业（有限合伙） | 1,101,432.00 | 2.73 | | 7 | 江苏毅达成果创新创业投资基金（有限合 | 747,100.00 | 1.85 | | | 伙） | | | | 8 | 苏琳 | 641,62 ...